Arrowhead Pharmaceuticals...

12.06
0.82 (7.30%)
At close: Apr 21, 2025, 3:59 PM
12.08
0.12%
After-hours: Apr 21, 2025, 06:04 PM EDT

Arrowhead Pharmaceuticals Statistics

Share Statistics

Arrowhead Pharmaceuticals has 137.32M shares outstanding. The number of shares has increased by 10.56% in one year.

Shares Outstanding 137.32M
Shares Change (YoY) 10.56%
Shares Change (QoQ) 10.35%
Owned by Institutions (%) 79.93%
Shares Floating 114.31M
Failed to Deliver (FTD) Shares 4.4K
FTD / Avg. Volume 0.21%

Short Selling Information

The latest short interest is 11.98M, so 9.5% of the outstanding shares have been sold short.

Short Interest 11.98M
Short % of Shares Out 9.5%
Short % of Float 12.61%
Short Ratio (days to cover) 7.07

Valuation Ratios

The PE ratio is -3.87 and the forward PE ratio is -3.07. Arrowhead Pharmaceuticals's PEG ratio is -0.02.

PE Ratio -3.87
Forward PE -3.07
PS Ratio 653.4
Forward PS 2.3
PB Ratio 12.51
P/FCF Ratio -3.84
PEG Ratio -0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arrowhead Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.74, with a Debt / Equity ratio of 2.75.

Current Ratio 6.74
Quick Ratio 6.74
Debt / Equity 2.75
Debt / EBITDA -0.91
Debt / FCF -0.84
Interest Coverage -18.58

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $5.83K
Profits Per Employee $-984.39K
Employee Count 609
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax -2.77M
Effective Tax Rate 0.45%

Stock Price Statistics

The stock price has increased by -49.58% in the last 52 weeks. The beta is 1, so Arrowhead Pharmaceuticals's price volatility has been higher than the market average.

Beta 1
52-Week Price Change -49.58%
50-Day Moving Average 15.62
200-Day Moving Average 20.41
Relative Strength Index (RSI) 43.87
Average Volume (20 Days) 2.12M

Income Statement

In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M and earned -599.49M in profits. Earnings per share was -5.

Revenue 3.55M
Gross Profit 3.55M
Operating Income -601.08M
Net Income -599.49M
EBITDA -561.51M
EBIT -580.11M
Earnings Per Share (EPS) -5
Full Income Statement

Balance Sheet

The company has 102.69M in cash and 510.55M in debt, giving a net cash position of -407.87M.

Cash & Cash Equivalents 102.69M
Total Debt 510.55M
Net Cash -407.87M
Retained Earnings -1.63B
Total Assets 1.01B
Working Capital 476.78M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -462.85M and capital expenditures -141.47M, giving a free cash flow of -604.32M.

Operating Cash Flow -462.85M
Capital Expenditures -141.47M
Free Cash Flow -604.32M
FCF Per Share -5.05
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -16927.06% and -16882.37%.

Gross Margin 100%
Operating Margin -16927.06%
Pretax Margin -17247.54%
Profit Margin -16882.37%
EBITDA Margin -15812.81%
EBIT Margin -16927.06%
FCF Margin -17018.3%

Dividends & Yields

ARWR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ARWR is $34.5, which is 186.1% higher than the current price. The consensus rating is "Buy".

Price Target $34.5
Price Target Difference 186.1%
Analyst Consensus Buy
Analyst Count 10
Stock Forecasts

Stock Splits

The last stock split was on Nov 17, 2011. It was a backward split with a ratio of 1:10.

Last Split Date Nov 17, 2011
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -2.9
Piotroski F-Score 3